Diagnostic role of coronary CT angiography in paroxysmal or first diagnosed atrial fibrillation

Dennis Rottländer, Martin Saal, Hubertus Degen, Miriel Gödde, Marc Horlitz, Michael Haude

ABSTRACT

Objectives The presence of coronary artery disease (CAD) in patients hospitalised with paroxysmal or first diagnosed atrial fibrillation (AF) has major implications for antithrombotic therapy and cardiovascular event rate. Coronary CT angiography (CCTA) is a feasible tool to identify patients with concealed CAD. We aimed to evaluate the diagnostic role of early CCTA in patients hospitalised with paroxysmal or first diagnosed AF.

Methods In a 5-year single-centre retrospective analysis, 566 patients with paroxysmal or first diagnosed AF who underwent CCTA were enrolled to investigate the presence of CAD.

Results In patients with paroxysmal or first diagnosed AF, CCTA revealed CAD (coronary artery stenosis ≥50%) in 39.2%. Cardiac catheterisation was performed in 31.6%, confirming CAD in 13.1% of all patients. In 8.0% percutaneous coronary intervention and in 0.5% coronary artery bypass grafting was performed. In patients with paroxysmal or first diagnosed AF: (1) angina pectoris per se does not predict CAD; (2) multivariable regression analysis revealed age, male sex and diabetes as risk factors for CAD in AF; (3) Framingham Risk Score for coronary heart disease and CHA2DS2-VASc-Score were relevant risk scores of CAD and (4) the classification of Coronary Artery Calcium score reference values according to the Multi-Ethnic Study of Atherosclerosis was a predictor of CAD.

Conclusion Patients with paroxysmal or first diagnosed AF are at risk for CAD, while CCTA is a feasible diagnostic tool for CAD. We recommend to integrate CT calcium scoring and CCTA into the diagnostic workup of patients with new-onset or paroxysmal AF.

INTRODUCTION

Atrial fibrillation (AF) is associated with an elevated risk of cardiovascular disease such as stroke and myocardial infarction. Even in patients with idiopathic AF without underlying cardiovascular disease, the cardiovascular event rate is significantly higher than in the general population. Coronary CT angiography (CCTA) revealed that patients with idiopathic AF more often suffer from concealed and sometimes advanced underlying coronary artery disease (CAD) than controls with sinus rhythm (SR).

Early treatment of concealed atherosclerosis could reduce progression of CAD and has major influence on the CHA2DS2-VASc-Score, thus, on potential stroke risk and indication of oral anticoagulation. CCTA clarifies the diagnosis of CAD, identifies patients requiring percutaneous coronary intervention (PCI) and might reduce the risk of myocardial infarction. The relevance and clinical consequences of CCTA for patients admitted to hospital with first-diagnosed or paroxysmal AF, regardless of their symptoms at the time of admission, remain unclear. The prevalence of CAD might even be higher than in patients with idiopathic AF, since CAD is present in over 20% of the AF population. Whether CAD per se predisposes via atrial ischaemia to AF and how AF interacts with coronary artery perfusion are uncertain. Recent studies suggest sympathetic activation driven positive
feedback mechanisms contributing to higher mortality of both diseases.7

Several studies of patients admitted to a chest pain unit suggest a beneficial effect of Coronary Artery Calcium (CAC) scoring in risk stratification in AF patients with intermediate pretest likelihood for CAD.8 9 Yet, these studies were conducted in comparably small and preselected study populations at a priori elevated risk for CAD. Recently, Nous et al reported the prognostic value of CCTA in identifying CAD in a small AF patient cohort, emphasising the benefit of CCTA in long term clinical follow-up, but lacking short-term clinical consequences.4 Also, none of the published trials used cardiac catheterisation to further evaluate CAD in pathological CCTA.

We aimed to describe the prevalence of CAD diagnosed by CCTA in a representative cohort with paroxysmal or first diagnosed AF and to evaluate the benefit of CCTA derived CAD diagnosis. For the first time, we provide data on invasive coronary angiography and the need of coronary intervention in patients admitted to hospital with first diagnosed or paroxysmal AF with significant CAD detected by prior CCTA.

METHODS
The study was performed in compliance with the Declaration of Helsinki. An individual written consent was obtained by every patient. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Study participants
The study design is summarised in figure 1. The study cohort comprised 1308 consecutive patients admitted to our hospital with AF between 1 January 2009 and 1 May 2014 who underwent CCTA. Exclusion criteria are listed in figure 1. Patients with persistent, long-term persistent or permanent AF were excluded because of impaired myocardial perfusion, low CCTA image quality due to pulsation artefacts and advanced atrial remodelling leading to atrial cardiomyopathy.10 11 Patients with spontaneous or iatrogenic conversion into SR were included into the final study cohort. Furthermore, in all patients ECG, echocardiography, CCTA and where available coronary angiography were analysed. Patients were afterwards divided into two groups: (1) patients with AF and significant CAD (CAD-AF) and (2) patients with AF in the absence of significant coronary stenosis (noCAD-AF). Symptoms in AF patients were classified according to the European Heart Rhythm Association (EHRA) classification.12

Definition of AF
AF was defined as the presence of AF on ECG during the admission to hospital. Electrocardiographic AF was defined as the presence of an irregular rhythm with fibrillatory waves, no defined P-waves and irregular R-wave distances. AF was subclassified into newly diagnosed or paroxysmal AF.1

Definition of CAD
Diagnosis of CAD was established if CCTA or coronary angiography presented a reduction of 50% or more of the luminal diameter of the coronary arteries.13 A significant stenosis of the left main artery was considered to be a two vessel disease. Localisation of coronary stenosis was established according to definitions of coronary artery segment as previously described.14

Coronary CT angiography
In all patients calcium scoring including determination of the Agatston score15 and calcium mass were performed. Patients were categorised using the CAC score reference values assessed by the Multi-Ethnic Study of Atherosclerosis (MESA).16 CT scans were performed using a multislice Brilliance iCT scanner (Phillips Healthcare, Cleveland, Ohio, USA) with a collimation of 256*0.6 mm and rotation time 0.26 s in accordance with the Society of Cardiovascular CT guidelines.17 CCTA was preferably performed in ECG-gated step and shoot technique with a tube current of 200–360 mA at a voltage of 10 kV. Native CT for calculation of the calcium mass was performed at 120 kV. For automatic bolus tracking, a region of interest was placed in the descending thoracic aorta at a threshold of 150 HU. Sublingual application of 0.4 mg glyceryltrinitrate was mandatory before each examination. When necessary, intravenous metoprolol (5 mg) was injected to reach heart rates <65/min. Steady injection of 70 mL contrast agent (Imeron 350) with a flow of 5.7 mL/s was followed by flushing with 50 mL saline. The majority of CCTAs was performed by prospective ECG gating at 78% RR-interval with a slice thickness of 0.5 mm and a reconstruction interval of 0.3 mm. CCTAs were analysed by two investigators with long-term experience on the field of cardiac CT evaluation (one radiologist and one cardiologist), which were both blinded to the medical data. Coronary arteries were evaluated according to the segment classification of the American Heart Association.14

Left heart catheterisation
Left heart catheterisation was performed as previously described and left ventricular ejection fraction was estimated via angiography.18 Coronary arteriography was carried out according to the technique of Judkins using 5F catheters.19

Statistical analysis
Statistical analysis was performed using PASW statistics V.18 software (SPSS). All variables were tested for normal distribution with the Kolmogorov-Smirnov test. In the case of normal distribution the results are given as mean±SE of mean, otherwise as median and 95% CI. Differences between groups and subgroups were evaluated by χ² test for discrete variables and Student’s t test for continuous variables. For ordinal data Mann-Whitney-U test was used. All clinical covariates showing a univariate relation with the presence of CAD were included in a logistic regression model and 95% CIs were calculated.
Coronary artery disease

Calibration of the model was checked by the Hosmer-Lemeshow statistic. Statistical significance was assumed at \( p<0.05 \).

RESULTS
Baseline characteristics
A total of 566 patients with paroxysmal or first diagnosed AF were identified to meet inclusion criteria in this retrospective study (Figure 1). Forty-five patients were excluded due to a known history of CAD. In the study population, 27.4\% had paroxysmal AF, whereas 72.6\% presented with first diagnosed AF. The demographic variables of the study population are shown in Table 1.

A total of 48.6\% of the patients were male. Mean age accounts for 67.8±0.5 years. Dyspnoea at admission was found in 29.3\% and angina pectoris in 26.3\%. Most of the patients at admission were categorised in EHRA class II (EHRA I 18.2\%, EHRA II 56.4\%, EHRA III 23.5\%, EHRA

Figure 1 Study design CCTA-AF trial. AF, atrial fibrillation; CCTA, coronary CT angiography; CAD, coronary artery disease; MESA, Multi-Ethnic Study of Atherosclerosis; PROCAM, Prospective Cardiovascular Munster (study); NTproBNP, N-terminal pro Brain natriuretic peptide.
Table 1  Baseline characteristics

| Characteristics                          | CTA-AF   | noCAD-AF | CAD-AF    | P value* |
|-----------------------------------------|----------|----------|-----------|----------|
| Age (years)                             | 566 67.8±0.5 | 492 67.2±0.5 | 74 71.5±1.1 | <0.01    |
| Male                                    | 275 48.6% | 230 46.7% | 45 60.8%   | 0.02     |
| Female                                  | 291 51.4% | 262 53.3% | 29 39.2%   | 0.02     |
| Heart rate (1/min)                      | 566 116.1±1.1 | 492 116.2±1.2 | 74 115.4±3.0 | 0.79     |
| Type of atrial fibrillation             |          |          |           |          |
| First diagnosed AF                      | 411 72.6% | 362 73.6% | 49 66.2%   | 0.02     |
| Paroxysmal AF                           | 155 27.4% | 130 26.4% | 25 33.8%   | 0.02     |
| Conversion to SR                        |          |          |           |          |
| Spontaneous conversion                  | 296 52.3% | 257 52.2% | 39 52.7%   | 0.75     |
| Medical cardioversion                   | 7 1.2%    | 6 1.2%    | 1 1.4%     | 0.75     |
| Electrical cardioversion                | 263 46.5% | 229 46.5% | 34 45.9%   | 0.75     |
| Patients history                        |          |          |           |          |
| Arterial hypertension                   | 420 74.2% | 358 72.8% | 62 83.8%   | 0.04     |
| RR systolic (at admission, mm Hg)       | 566 137.2±0.8 | 492 136.7±0.9 | 74 140.6±2.4 | 0.11     |
| RR diastolic (at admission, mm Hg)      | 566 83.1±0.7 | 492 83.3±0.6 | 74 81.6±1.6 | 0.32     |
| Hyperlipidaemia                         | 222 39.2% | 197 40.0% | 25 33.8%   | 0.30     |
| Obesity                                 | 157 27.7% | 135 27.4% | 22 29.7%   | 0.92     |
| Body mass index (kg/m²)                 | 566 27.9±0.2 | 492 27.9±0.2 | 74 27.8±0.5 | 0.79     |
| Family history of cardiovascular disease| 106 18.7% | 88 17.9%  | 18 24.3%   | 0.19     |
| Diabetes mellitus                       | 83 14.7%  | 61 12.4%  | 22 29.7%   | <0.01    |
| Pulmonary disease                       | 53 9.4%   | 45 9.1%   | 8 10.8%    | 0.65     |
| History of smoking                      | 51 9.0%   | 44 9.0%   | 7 9.5%     | 0.89     |
| Current smoking                         | 49 8.7%   | 43 8.7%   | 6 8.1%     | 0.86     |
| TIA/stroke                              | 23 4.1%   | 19 3.9%   | 4 5.4%     | 0.80     |
| Hyperthyrodesim                         | 14 2.5%   | 12 2.4%   | 2 2.7%     | 0.89     |
| CHA2DS2-VASC-Score                      | 566 2.5±0.1 | 492 2.4±0.1 | 74 3.4±0.2 | <0.01    |
| PROCAM score (%)                        | 422 17.0±0.9 | 378 15.7±0.8 | 44 27.6±1.7 | <0.01    |
| Framingham Risk Score (%)               | 467 10.8±0.4 | 403 10.3±0.4 | 64 14.2±0.9 | 0.01     |
| Echocardiography parameters             |          |          |           |          |
| Left ventricular hypertrophy            | 320 56.5% | 274 55.7% | 46 62.2%   | 0.25     |
| Interventric septum thickness (diastole, mm) | 566 1.1±0.1 | 492 1.1±0.1 | 74 1.2±0.1 | 0.18     |
| Left atrial dilatation                  | 197 34.8% | 176 35.8% | 21 28.4%   | 0.15     |
| Left atrial diameter (cm)               | 566 3.7±0.1 | 492 3.7±0.1 | 74 3.7±0.1 | 0.91     |
| LVEF (%)                                | 566 60.3±0.3 | 492 60.4±0.3 | 74 59.6±0.8 | 0.37     |
| sPAP (mm Hg)                            | 566 25.5±0.6 | 492 25.1±0.6 | 74 27.8±1.5 | 0.12     |
| Laboratory results                      |          |          |           |          |
| NT-pro-BNP (pg/mL)                      | 566 1412.5±59.7 | 492 1359.6±62.6 | 74 1674.7±85.2 | 0.02     |
| Estimated glomerular filtration rate (mL/min) | 566 74.8±0.8 | 492 75.4±0.8 | 74 71.0±2.3 | 0.08     |
| Glucose (mg/dL)                         | 566 118.9±1.5 | 492 117.9±1.6 | 74 125.1±5.4 | 0.11     |
| Total cholesterol (mg/dL)               | 468 203.7±1.9 | 404 204.2±1.9 | 64 200.8±6.0 | 0.54     |

Continued
Coronary artery disease

IV 1.9%). Transthoracic echocardiography revealed preserved ejection fraction (60.5±0.3%) and normal systolic pulmonary artery pressure (sPAP, 25.5 mm Hg ±0.6). Left ventricular hypertrophy was documented in 56.5% of the patients, while the left atrium was dilated in 34.8%. However, N-terminal pro brain natriuretic peptide (NT-pro-BNP) at admission was significantly elevated (1412.5 pg/mL±59.7). Spontaneous conversion into SR was observed in 52.3%, while in 1.2% medical cardioversion and in 46.5% electrical cardioversion was conducted. CHA2DS2-VASc Score was determined, in most cases indicating long-term oral anticoagulation (2.5±0.1). Prospective Cardiovascular Munster (PROCAM Risk Score) (17±0.9% ; n=422) and Framingham Risk Score (10.8±0.4% ; n=467) were obtained where applicable.20 21

Table 1  Continued

| Characteristics                                                                 | CTA-AF       | n | % or mean±SEM | noCAD-AF     | n | % or mean±SEM | CAD-AF       | n | % or mean±SEM | P value* |
|---------------------------------------------------------------------------------|--------------|---|----------------|--------------|---|----------------|--------------|---|---------------|----------|
| High-density lipoprotein cholesterol (mg/dL)                                    | 468          | 56.5±0.8       | 404          | 56.8±0.9    | 64          | 54.2±2.4       | 0.27         |
| Low-density lipoprotein cholesterol (mg/dL)                                     | 468          | 123.9±1.7      | 404          | 124.1±1.8   | 64          | 123.2±5.3      | 0.87         |
| Medication                                                                      |              |               |              |              |              |               |              |
| ACE-inhibitor/AT-1 antagonist                                                   | 408          | 72.1%          | 340          | 60.1%       | 68          | 91.9%          | <0.01        |
| Diuretics                                                                       | 253          | 44.7%          | 211          | 37.3%       | 42          | 56.8%          | 0.03         |
| Acetylsalicylic acid                                                            | 251          | 44.3%          | 220          | 44.7%       | 31          | 41.9%          | 0.24         |
| Statins                                                                         | 197          | 34.8%          | 168          | 34.1%       | 29          | 39.2%          | 0.51         |
| Thyroxine                                                                       | 129          | 22.8%          | 115          | 23.4%       | 14          | 18.9%          | 0.40         |
| Non-cardioselective calciumantagonist                                          | 101          | 17.8%          | 83           | 16.9%       | 18          | 24.3%          | 0.12         |
| Cumarine                                                                       | 89           | 15.7%          | 78           | 15.9%       | 11          | 14.9%          | 0.82         |
| Oral antidiabetics                                                              | 51           | 9.0%           | 41           | 8.3%        | 10          | 13.5%          | 0.15         |
| DOAC                                                                            | 34           | 6.0%           | 27           | 5.5%        | 7           | 9.5%           | 0.31         |
| Antiobstructive agents                                                          | 32           | 5.7%           | 29           | 5.9%        | 3           | 4.1%           | 0.52         |
| Clopidogrel                                                                     | 16           | 2.8%           | 13           | 2.6%        | 3           | 4.1%           | 0.32         |
| Digitoxin                                                                      | 13           | 2.3%           | 12           | 2.4%        | 1           | 1.4%           | 0.56         |
| Class-I antiarrhythmics                                                        | 12           | 2.1%           | 12           | 2.4%        | 0           | 0.0%           | 0.18         |
| Insulin                                                                        | 11           | 1.9%           | 8            | 1.6%        | 3           | 4.1%           | 0.16         |
| Dronedarone                                                                    | 10           | 1.8%           | 10           | 2.0%        | 0           | 0.0%           | 0.22         |
| Cardioselective calciumantagonist                                              | 3            | 0.5%           | 2            | 0.4%        | 1           | 1.4%           | 0.50         |
| Amiodarone                                                                     | 1            | 0.2%           | 1            | 0.2%        | 0           | 0.0%           | 0.70         |
| Betablocker                                                                     | 433          | 76.5%          | 374          | 76.0%       | 59          | 79.7%          | 0.48         |
| Dyspnoea                                                                       | 166          | 29.3%          | 139          | 28.3%       | 27          | 36.5%          | 0.15         |
| Stable Angina                                                                   | 149          | 26.3%          | 131          | 26.6%       | 18          | 24.4%          | 0.42         |
| EHRA I                                                                         | 103          | 18.2%          | 89           | 18.1%       | 14          | 18.9%          | 0.53         |
| EHRA II                                                                        | 319          | 56.4%          | 282          | 57.3%       | 37          | 50.0%          | 0.53         |
| EHRA III                                                                       | 133          | 23.5%          | 111          | 22.6%       | 22          | 29.7%          | 0.53         |
| EHRA IV                                                                        | 11           | 1.9%           | 10           | 2.0%        | 1           | 1.4%           | 0.53         |

*noCAD-AF vs CAD-AF.
ACE, angiotensin converting enzyme; AF, atrial fibrillation; AT-1 antagonist, angiotensin-receptor-1 antagonist; CAD, coronary artery disease; CTA, cardiac CT angiography; DOAC, direct oral anticoagulants; EHRA, European Heart Rhythm Association; LVEF, left ventricular ejection fraction; NT-pro-BNP, n-terminal pro brain natriuretic peptide; PROCAM, Prospective Cardiovascular Munster (study); RR, blood pressure; SEM, SE of mean; sPAP, systolic pulmonary artery pressure; SR, sinus rhythm.

Coronary CT angiography
Mean Agatston score and mean calcium mass were elevated in patients with AF (120.91±8.7, 27.61±2.6; figure 2A). A negative calcium score was found in 35.9% of the study population (figure 2B). In patients with paroxysmal or first diagnosed AF CAD (≥50% stenosis) was found in 39.2% using CCTA (figure 2C). The mean
percentile MESA showed intermediate risk for significant CAD (36.51±1.4, figure 2A,D) in patients with AF. In CCTA, coronary stenosis was located in 44.1% in the left artery descending (LAD), while left circumflex artery (LCX) and right coronary artery (RCA) were affected by significant coronary stenosis in 18.0% and 17.4% of the study population, respectively (figure 2E).

Cardiac catheterisation
To verify the results of CCTA, cardiac catheterisation was performed in patients with significant coronary stenosis (≥50% stenosis) documented by CCTA. Due to the results of CCTA, cardiac catheterisation was performed in 179 patients (31.6%). Left ventricular angiography revealed normal ejection fraction (LVEF, 74.44±0.7, figure 3A) and elevated left ventricular enddiastolic pressure (12.93±0.4, figure 3A). Significant CAD in the coronary angiogram was observed in 13.1% of all patients (figure 3B), resulting in PCI in 8.0% and in coronary artery bypass grafting (CABG) in 0.5% (figure 3C). LAD was the predominantly affected segment (44.3%, figure 3D). Target vessels for PCI were the LAD (40%), followed by RCA (20%), LCX (15.5%) and OM (11.1%). Notably, in patients with negative calcium scoring (Agatston score 0) only one patient needed PCI due to a soft-plaque (0.5%) indicating these patients to be at very low risk of significant CAD.

Characteristics of patients with significant CAD in AF
In 74 patients significant CAD was documented using coronary angiography (AF-CAD). This subgroup was compared with patients without significant CAD (AF-noCAD) in order to evaluate parameters or risk factors for CAD. Demographic variables of both groups are shown in table 1. Univariate analysis revealed age, male sex, arterial hypertension and diabetes mellitus to be significant risk factors for CAD in AF (AF-CAD: 71.5±1.1 years, 60.8%, 83.8%, 29.7% vs AF-noCAD: 67.2±0.5, 46.7%, 72.8%, 12.4%, p<0.05). Furthermore, all evaluated risk scores (CHA2DS2-VASc-Score, Framingham Risk Score, PROCAM Risk Score) were markedly increased in the AF-CAD group (AF-CAD: 3.4±0.2, 14.2±0.9, 27.6±1.7 vs AF-noCAD: 2.4±0.1, 10.3±0.4, 15.7±0.8, p<0.05). No significant difference in symptoms at admission (angina pectoris or dyspnoea) between both groups could be observed (AF-CAD: 24.4%, 36.5% vs AF-noCAD: 26.6%, 28.3%, p>0.05). Therefore, angina pectoris is no predictor for significant CAD in patients admitted to hospital with an episode of first diagnosed or paroxysmal AF. NT-pro-BNP was significantly increased in AF-CAD (AF-CAD: 1763.6±184 vs AF-noCAD: 1359.6±62.6, p<0.05).

EHRA classification showed no significant difference between both subgroups (table 1). Calcium scoring was higher in patients with significant CAD (Agatston score: AF-noCAD 96.5±8.3 vs AF-CAD 283±8.7; calcium mass: AF-noCAD 20.6±1.7 vs AF-CAD 74.4±14.9, p<0.05, figure 4A). The mean percentile CAC was increased in patients with significant CAD (AF-noCAD 33.1±1.5 vs AF-CAD 59.4±3.3, p<0.05, figure 4A).

In variables showing a univariate relation with CAD, a multivariable regression analysis was performed (table 2).
DISCUSSION

In this retrospective analysis, we investigated the clinical relevance of early coronary calcium scoring and CCTA in patients with first diagnosed or paroxysmal AF. CCTA showed CAD in 39.2% of patients with AF. Subclinical CAD is known to be significantly more frequent in patients with idiopathic AF compared with SR controls (49% vs 34%), while obstructive CAD was found in 4% of patients with idiopathic AF.3 Furthermore, 40% of patients with paroxysmal and persisting AF showed obstructive CAD in CCTA,22 which matches our results. This strengthens the hypothesis that AF could be a marker of CAD. For the first time, we report data for calcium scoring and CCTA in AF followed by cardiac catheterisation in obstructive CAD. Invasive coronary angiography revealed obstructive CAD in 13.1% of the patients. Furthermore, 8.0% of the patients required PCI and 0.5% CABG. This demonstrates that patients with first diagnosed or paroxysmal AF are at risk of obstructive CAD.

Nous et al4 reported 26% of patients with obstructive CAD in CCTA and 29% of the patients with CAD underwent coronary revascularisation. This is moderately higher than in our study, where 20.3% underwent coronary intervention (45 of 222 patients with CAD in CCTA underwent PCI and two received CABG). This might be due to slightly different baseline characteristics, as our cohort presents less well factors for CAD, in particular regarding current or history of smoking. Yet, the need for PCI in our study was far higher than in studies investigating significant CAD by CCTA in a cohort of 73 patients admitted to a chest pain unit.8 9 In this cohort, 7% needed coronary intervention (two patients with PCI and three with CABG). This comparatively low necessity of intervention emphasises our findings that there is only a weak association between AF patients admitted to hospital due to chest pain and relevant CAD. This applies especially for patients presenting with atypical chest pain, which was one inclusion-criteria in the aforementioned studies.

Angina pectoris during AF was not a significant predictor of CAD in our cohort, which has major implications for the clinical management of patients with first diagnosed or paroxysmal AF. This suggests that patients with AF and concomitant angina pectoris need not universally be classified as acute coronary syndrome, unless further diagnostics confirm this diagnosis. In the long term, identification of patients at high risk for CAD might be mandatory to reduce cardiovascular events. Therefore, early detection of underlying CAD in AF using CCTA will lead to adequate clinical treatment of risk factors and CAD. For example, certain anti-arrhythmics must be considered carefully and lipids need to be monitored and treated more intensively.23 24 Newly diagnosed CAD might also trigger the need for oral anticoagulation due to elevated CHA2DS2-VASc-Score.1 Furthermore, we showed calcium scoring to be a useful diagnostic tool. Diabetes mellitus is a major risk factor for CAD also in AF. In the Framingham Risk Score, but not in the PROCAM-Risk-Score, Diabetes mellitus is included in risk assessment indicating that Framingham Risk Score is more suitable for risk assessment in patients with AF.20 21 25 The non-inclusion

---

**Figure 3** Coronary angiography in patients with AF and pathological CCTA. (A) Angiography results (mean±SEM). (B) Percentage of CAD positive patients (≥50% stenosis) using coronary angiography. (C) Percentage of patients who underwent PCI or CABG. (D) Localisation of coronary artery stenosis using coronary angiography. AF, atrial fibrillation; CAD, coronary artery disease; LAD, left artery descending; LCX, left circumflex artery; LMCA, left main coronary artery; LV-EF, left ventricular ejection fraction; LVEDP, left ventricular enddiastolic pressure; OM, obtuse marginal branch; PDA, posterior descending artery; RCA, right coronary artery; RD, diagonal Branch; RPLA, right posterolateral artery.
The incidence of coronary events in AF varies among studies, since the selection criteria of patients or the definition of coronary events are heterogeneous. The RE-LY trial showed an incidence of 0.53% for myocardial infarction during a 2-year follow-up in the warfarin arm. The REACH registry, where patients with high-risk profiles were enrolled, reported 1.36% non-fatal myocardial infarction in AF patients. To avoid cardiovascular events in patients with AF, the presence of CAD should carefully be controlled. The present study investigated the benefit of early CCTA in AF and aimed to identify the patients at high risk for relevant CAD. Early detection and treatment of even subclinical CAD is useful to prevent coronary events and to identify patients for oral anticoagulation regarding the CHA2DS2-VASc-Score. 

In summary, this study demonstrated that patients with paroxysmal or first diagnosed AF are at risk for CAD. For the first time we evaluated a large cohort of patients with AF and CCTA which underwent invasive coronary angiography in case of pathological CCTA. Age, male sex, and diabetes mellitus are risk factors for CAD in AF, while Framingham Risk Score and CHA2DS2-VASc-Score are significant risk scores for CAD in AF. The classification according to MESA is a valuable CT predictor for CAD in AF. This

| Table 2 | Regression analysis of risk factors, risk scores and calcium scoring |
|---------|--------------------------------------------------|
| **OR**  | **95% CI** | **P value** |
| **Risk factors** | | | |
| Age (years) | 1.053 | 1.023 to 1.084 | <0.01 |
| Male sex (%) | 1.042 | 1.246 to 1.714 | <0.01 |
| Diabetes mellitus (%) | 2.768 | 1.536 to 4.990 | <0.01 |
| **Risk scores** | | | |
| CHA2DS2-VASc-Score | 1.398 | 1.060 to 1.844 | 0.018 |
| Framingham Risk Score | 1.851 | 1.060 to 3.244 | 0.047 |
| **Calcium scoring** | | | |
| Calcium Mass | 1.497 | 1.098 to 1.214 | 0.016 |
| Percentile MESA | 1.016 | 1.106 to 1.627 | <0.01 |

Multivariable regression analysis of risk factors, risk scores and calcium scoring parameters related to the presence of significant coronary artery disease in paroxysmal or first diagnosed AF. Age, male sex and diabetes were significant risk factors for CAD in first diagnosed or paroxysmal AF. Furthermore, CHA2DS2-VASc-Score and Framingham Risk Score showed a significant association with CAD. PROCAM risk score failed to reach significance. The analysis of calcium scoring revealed calcium mass and mean percentile CAC to be predictive for significant CAD in AF.

AF, atrial fibrillation; CAC, coronary artery calcium; CAD, coronary artery disease; MESA, Multi-Ethnic Study of Atherosclerosis.

![Comparison of patients with early stage AF in absence (AF-noCAD) or presence of significant CAD (AF-CAD). (A) Comparison of calcium scoring including the Agatston Score, calcium mass and percentile acquired by the Coronary Artery Calcium Score reference values assessed by the Multi-Ethnic Study of Atherosclerosis (MESA) (mean±SEM). (B) Patients categorised into groups using the Percentile MESA. *P<0.05. AF, atrial fibrillation; CAD, coronary artery disease;](image-url)
has major impact on CHA\textsubscript{2}DS\textsubscript{2}-VASc-Score, antithrombotic therapy and probably on the cardiovascular event rate. Overall, CCTA is a feasible diagnostic tool for CAD in patients with first diagnosed or paroxysmal AF. Therefore, we recommend to integrate CT calcium scoring and CCTA into the diagnostic workup of patients with new-onset or paroxysmal AF.

**STUDY LIMITATIONS**

This study is of retrospective nature. A prospective randomised trial is needed to verify our results. Regarding prevention of cardiovascular events due to early detection of CAD in AF, a long-term follow-up would be needed to detect significant differences due to the low short-term incidence of cardiovascular events in these patients.

**Twitter** Dennis Rottländer @DFrottlander

**Contributors** DR: conceptualisation; data collection, analysis and interpretation; drafting; final approval. MS: data collection, analysis and interpretation; drafting; final approval. MG: data collection. HD: conceptualisation, critical revision. MH: conceptualisation; critical revision; final approval.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** HD is a consultant for Biotronik and Cardiac Dimensions. MH received institutional grants/research supports from Abbott, Biotronik and receipt of honoraria or consultation fees from Biotronik, Cardiac Dimensions, OrbusNeich and Philips. The other authors have nothing to declare.

**Patient consent for publication** Not required.

**Ethics approval** Since we performed a retrospective analysis of our patient database, no ethical approval is required due to local regulations.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD** Dennis Rottländer http://orcid.org/0000-0002-8789-9092

**REFERENCES**

1 Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS). *Eur Heart J* 2021;42:373–498.

2 Potpara TS, Stankovic GR, Beleslin BD, et al. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade atrial fibrillation study. *Chest* 2012;141:339–47.

3 Weis B, Pisters R, Haest RJ, et al. Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. *Heart Rhythm* 2012;9:1923–9.

4 Nous FMA, Budde RPJ, van Dijikman ED, et al. Prognostic value of subclinical coronary artery disease in atrial fibrillation patients identified by coronary computed tomography angiography. *Am J Cardiol* 2020;126:16–22.

5 Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. *Chest* 2010;137:263–72.

6 Michnikiewicz E, Młodawska E, Łopatowska P, et al. Patients with atrial fibrillation and coronary artery disease - Double trouble. *Adv Med Sci* 2018;63:30–5.

7 Lieder H, Breithardt G, Heusch G. Fatal attraction - A brief pathophysiology of the interaction between atrial fibrillation and myocardial ischemia. *Int J Cardiol* 2018;254:132–5.

8 Breuckmann F, Olligs J, Hinrichs L, et al. Coronary artery calcium as an independent surrogate marker in the risk assessment of patients with atrial fibrillation and an intermediate pretest likelihood for coronary artery disease admitted to a German chest pain unit. *Clin Cardiol* 2016;39:157–64.

9 Koopmann M, Hinrichs L, Olligs J, et al. Cardiac computed tomography in patients with symptomatic new-onset atrial fibrillation, rule-out acute coronary syndrome, but with intermediate pretest probability for coronary artery disease admitted to a chest pain unit. *Eur J Med Res* 2018;23:6.

10 Range FT, Schäfers M, Acil T, et al. Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. *Eur Heart J* 2007;28:2223–30.

11 Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/ SOLAACE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. *Europe J* 2016;18:1455–90.

12 Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence Network and the European Heart Rhythm Association. *Europe J* 2007;9:1006–23.

13 Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. *Eur Heart J* 2019;40:237–69.

14 Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. *Circulation* 1975;51:5–40.

15 Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol* 1990;15:827–32.

16 McClelland RL, Chung H, Detrano R, et al. Distribution of coronary artery calcium by race, gender, and age: results from the multi-ethnic study of atherosclerosis (MESA). *Circulation* 2006;113:30–7.

17 Abbara S, Blanke P, Maroules CD, et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee: endorsed by the North American Society for Cardiovascular Imaging (NASCI). *J Cardiovasc Comput Tomogr* 2016;10:435–49.

18 Dodge HT, Sandler H, Ballew DW, et al. The use of biplane angiography for the measurement of left ventricular volume in man. *Am Heart J* 1960;60:762–76.

19 Judkis MP. Percutaneous Transfemoral selective coronary arteriography. *Radiol Clin North Am* 1968;6:467–92.

20 Assmann G, Schulte H, Cullen P, et al. Assessing risk of myocardial infarction and stroke: new data from the prospective cardiovascular Münster (PROCAM) study. *Eur J Clin Invest* 2007;37:925–32.

21 D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. *Circulation* 2008;117:743–53.

22 Nucifora G, Schuijf JD, van Werkhoven JM, et al. Relationship between obstructive coronary artery disease and abnormal stress testing in patients with paroxysmal or persistent atrial fibrillation. *Int J Cardiovasc Imaging* 2011;27:777–85.

23 Greenberg HM, Dwyer EM, Hochman JS, et al. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in cast I. *Br Heart J* 1995;74:631–5.

24 Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2020;41:407–77.

25 Kannel WB, Abbott RD, Savage DD, et al. Coronary heart disease and atrial fibrillation: the Framingham study. *Am Heart J* 1983;106:389–96.

26 Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med Overseas Ed* 2009;361:1139–51.

27 Goto S, Bhatt DL, Röther J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. *Am Heart J* 2008;156:655–63.

28 Miyasaka Y, Barnes ME, Ghosh BJ, et al. Coronary ischemic events after first atrial fibrillation: risk and survival. *Am J Med* 2007;120:357–63.